Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
01 2023
Historique:
received: 21 08 2022
revised: 22 10 2022
accepted: 28 10 2022
pubmed: 25 11 2022
medline: 31 12 2022
entrez: 24 11 2022
Statut: ppublish

Résumé

To determine the prevalence of underlying high-intermediate (high-IM) and high-risk endometrial cancer (EC) in patients with preoperative diagnosis of Endometrial intraepithelial neoplasia (EIN) and to assess the impact of the information retrieved from the sentinel lymph node (SLN) on adjuvant therapy. Retrospective cohort study of women undergoing hysterectomy, optional bilateral salpingo-oophorectomy (BSO) and lymph nodes assessment for EIN between December 2007 and August 2021. One hundred and sixty two (162) eligible patients were included, of whom 101 (62.3%) had a final diagnosis of EIN, while 61 (37.7%) were ultimately diagnosed with carcinoma. Out of 15 patients with high-IM to high-risk disease (9.25% of all EIN), 12 had grade 2-3 EC including 8 with >50% myometrial invasion, 2 with serous subtype, 1 with cervical invasion and 2 with pelvic lymph nodes involvement. Of the 3 patients with grade 1 EC, one patient had disease involving the adnexa and 2 patients had tumor invading >50% of the myometrium and with lymphovascular space invasion (LVSI). Ten patients received vaginal brachytherapy after surgery, 3 patients with extrauterine spread were treated with systemic chemotherapy followed by vaginal brachytherapy and pelvic external-beam radiotherapy and 2 patients with early-stage serous carcinoma received chemotherapy followed by vaginal brachytherapy. Information from SLN, even when negative, can be helpful in the management of patients with EC after preoperative EIN, as some patients are found to have high-IM to high-risk disease on final pathology. These patients would require either re-staging surgery or adjuvant external beam radiotherapy, both could be avoided by proper staging.

Identifiants

pubmed: 36423445
pii: S0090-8258(22)01910-2
doi: 10.1016/j.ygyno.2022.10.023
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-113

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Emad Matanes (E)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montreal, Quebec, Canada; Department of Obstetrics and Gynecology, Rambam Medical Center, Technion, Haifa, Israel.

Zainab Amajoud (Z)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Liron Kogan (L)

Department of Obstetrics and Gynecology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.

Cristina Mitric (C)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Sara Ismail (S)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Oded Raban (O)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

David Knigin (D)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Gabriel Levin (G)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Boris Bahoric (B)

Division of Radiation Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Alex Ferenczy (A)

Department of Pathology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Manuela Pelmus (M)

Department of Pathology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Magali Lecavalier-Barsoum (M)

Division of Radiation Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Susie Lau (S)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Shannon Salvador (S)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Walter H Gotlieb (WH)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montreal, Quebec, Canada. Electronic address: walter.gotlieb@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH